Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Mediwound (MDWD – Research Report), retaining the price target of $25.00.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors that highlight Mediwound’s promising future prospects. The company’s ongoing clinical advancements, particularly with EscharEx, are a significant driver. The Phase 3 VALUE study for EscharEx in venous leg ulcer (VLU) patients is progressing well, with a high probability of success, and plans for a Phase 2 study to compare EscharEx with existing collagenase products are underway. These efforts are expected to support regulatory submissions and enhance market adoption.
Additionally, the recent update to Medicare’s local coverage determination policy is anticipated to bolster EscharEx’s adoption, as it aligns with the product’s capabilities in wound debridement. Furthermore, the strong demand for NexoBrid, despite current supply limitations, and the company’s plans to reach full operational capacity by the end of 2025, further reinforce the positive outlook. These strategic initiatives and partnerships position Mediwound well for future growth, justifying the Buy rating.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $25.00 price target.